Built for health systems.
Designed for scale.
Unified platform eliminates integration risk. One vendor replaces 6–7 disconnected systems — reducing procurement cycles by an estimated 8 months. Open standards, data portability guarantees, and modular architecture ensure zero vendor lock-in.
The Problem We Solve
Clinical development is broken. These are the numbers that prove it — and the reason medinovAI exists.
Three Diversified Revenue Engines
Eliminating single-product concentration risk through vertical integration. Recurring enterprise subscriptions with multi-year commitments.
Recurring SaaS Revenue
Multi-year enterprise SaaS commitments. Land-and-expand: eTMF → CTMS → LIS → EDC → full platform. Each module adoption increases switching costs.
- Multi-year MSAs
- Land-and-expand model
- 100% enterprise clients
Clinical Services Revenue
myOnsite per-visit clinical services under master service agreements. Protocol-bound visit volume commitments aligned to sponsor enrollment projections.
- Protocol-bound volumes
- Forward revenue visibility
- Zero consumer exposure
Biospecimen Revenue
ICMR-licensed, FDA-authorized procurement. Zero regulatory incidents. Premium pricing for compliance certainty. DescartesBio trans-sovereign pipeline.
- ICMR-licensed
- FDA-authorized
- Premium compliance pricing
Structural Competitive Moats
Advantages that cannot be replicated by any single competitor in the market.
Only entity with simultaneous first-party ownership of IND-authorized DCT phlebotomy + AI-native clinical SaaS + ICMR-licensed biospecimen procurement + direct FDA ESG eCTD submission
MSKCC — #1 NCI-designated oncology institution — selected myOnsite as IND-authorized decentralized phlebotomy provider
DescartesBio 15,000+ clinically-annotated oncology specimens representing South Asian genomic architectures absent from all major Western biobank reference populations
Vertical integration collapses 7 independent MSAs, SOC 2 attestation reviews, and BAA negotiations into a single contractual framework
Cryptographic hash chain provenance — mathematically verifiable proof from needle to NDA — no competitor can replicate
From Discovery to Strategic Partnership
Reducing 18-month vendor cycles to accelerated value delivery.
Discovery
AI-personalized presentation adapts in real-time to your role, interests, and organization — eliminating generic sales decks.
Qualification
Tiered access levels reveal progressively deeper intelligence — from public overview through NDA-protected documentation.
Proof of Value
Pre-configured environment demonstrates full capabilities within 30 days — de-risking the commitment decision with real trial data.
Land & Expand
Start with eTMF, add CTMS, then LIS and EDC — each module shares the same data, auth, and audit infrastructure.
Access the Full Investment Thesis
The full 28-slide presentation — including platform architecture deep-dive, revenue model, competitive analysis, team, and financial projections — is available to qualified investors and strategic partners. Access is currently available to US-based organizations.